Best of: The future of exercise

Episode Summary

Executive Summary: The episode explores how exercise influences metabolism at the molecular level, focusing on Stanford biochemist Jonathan Long’s work on exercise-induced chemicals like LAC-PHE that can suppress appetite and potentially aid weight loss. It also explains why GLP-1 drugs and metformin are part of a broader story of basic science translating into therapies, while cautioning that an “exercise pill” remains a long-term prospect.

Main Topics: Exercise chemistry and molecular signaling (Priority: 5/5): Long explains that his lab studies exercise from a chemical perspective, using molecules as clean handles to understand complex physiological states. Discovery of LAC-PHE (Priority: 5/5): A key exercise-inducible metabolite derived from lactate, LAC-PHE rises after intense exercise and suppresses feeding by acting through the gut-brain axis. Exercise, motivation, and brain pathways (Priority: 4/5): The conversation covers psychological preparation for exercise and emerging evidence that endocannabinoids contribute to motivation and runner’s high. Obesity, diabetes, and weight loss biology (Priority: 5/5): The discussion links obesity and type 2 diabetes to body weight, metabolic health, and the importance of preserving lean mass while reducing fat. Metformin and GLP-1 drugs as examples of translational science (Priority: 4/5): Long frames semaglutide/GLP-1 medicines and metformin as examples of decades-long basic research translating into powerful metabolic therapies. Prospects for an exercise pill (Priority: 5/5): The episode evaluates whether exercise pathways could be pharmacologically harnessed, emphasizing that this is still in the early discovery phase.

Key Arguments: Basic science on molecules can reveal mechanisms that are invisible from a purely medical view of exercise. LAC-PHE is a conserved exercise signal across many moving animals and may explain post-exercise appetite suppression. The molecule lasts far longer than lactate after strenuous exercise, suggesting it helps translate short bouts of activity into prolonged physiological effects. Trained people handle lactate better, so untrained individuals may show stronger LAC-PHE responses and potentially greater metabolic effects. Weight loss is beneficial regardless of method, but the ideal outcome is fat loss with preservation of lean mass through resistance training. Exercise should not be described loosely as a medicine; to make that analogy real, researchers must define exercise with molecular precision. Metformin and exercise converge on the same LAC-PHE pathway, showing that very different interventions can share underlying biology. An exercise pill is plausible in principle, but likely decades away and may require multiple compounds targeting different exercise benefits.

Data Points: GLP-1 development timeline: ~40 years - Long describes the path from basic endocrinology in the 1980s to modern GLP-1 weight-loss medicines. Recent therapeutic translation window: ~10 years - He says interest in GLP-1s’ therapeutic potential accelerated over the last decade. Exercise recommendation: 150 minutes per week - Russ cites the CDC-style exercise guidance as an example of how nonspecific exercise prescription is compared with modern drugs. LAC-PHE persistence in humans: 12–18 hours - After a treadmill test, LAC-PHE remains elevated long after lactate returns to baseline. Lactate normalization: ~1 hour - In the treadmill example, lactate levels return to baseline about an hour after exercise. Sprint test duration: 10 minutes - Used as an example of a high-intensity treadmill test that drives lactate and LAC-PHE up strongly. Metformin vs. sprint exercise: Metformin is a stronger inducer of LAC-PHE in humans - Long says metformin can raise LAC-PHE more than sprint exercise, according to reported findings. Podcast archive: 300+ episodes - Promotional mention at the end of the episode.

Pivotal Quotes: "we are where the GLP1 medicines were in the 1980s" — Jonathan Long: He uses this analogy to describe how early the field is in understanding exercise biology and translating it into therapies. "What we have to do is define physical activity at the resolution that we define modern medicine" — Jonathan Long: This summarizes his argument that exercise science needs molecular precision to become truly therapeutic. "metformin actually in people is a stronger inducer of Lakfee than sprint exercise" — Jonathan Long: He highlights the unexpected molecular overlap between a common diabetes drug and exercise physiology.

Implications: The episode suggests future obesity/diabetes therapies may come from decoding exercise chemistry, not just mimicking calories burned. It also reframes exercise science as a long-term drug-discovery pipeline rather than a quick route to an exercise pill.